瑞舒伐他汀对高血压病伴高脂血症患者血小板活化功能的影响被引量：2

下载PDF

导出

摘要目的探讨瑞舒伐他汀对高血压病伴高脂血症患者血小板活化功能的影响。方法选取1级、2级高血压病伴高脂血症患者120例,采用随机数字表法分为治疗组和对照组各60例。另选取年龄、性别等相匹配55例正常体检者作为健康组。对照组给予贝那普利10 mg,qd,po,治疗组在此基础上加用瑞舒伐他汀10 mg,qd,观察时间为4周。观察治疗前后血压、血脂、血小板计数(PLT)、血小板分布宽度(PDW)、平均血小板体积(MPV)、血小板α颗粒膜蛋白(GMP-140)变化。结果治疗组及对照组治疗前血压、总胆固醇(TC)、三酰甘油(TG)、低密度脂蛋白胆固醇(LDL-C)、PLT、PDW、MPV及GMP-140水平均高于健康组(P<0.05),而高密度脂蛋白胆固醇(HDL-C)低于健康组(P<0.05)。治疗组治疗4周后,与治疗前相比血压、TC、TG、LDL-C、PLT、MPV及GMP-140水平均明显下降(P<0.05),HDL-C水平升高(P<0.05);而对照组与治疗前相比血压、PLT、MPV水平均明显下降(P<0.05),其余指标治疗前后差异无统计学意义,两组治疗后TC、LDL-C、HDL-C、GMP-140水平比较差异有统计学意义(P<0.05)。治疗组相关分析显示GMP-140水平下降幅度与TC、TG、LDL-C下降幅度无相关性,r值分别为0.227,0.326,0.173(P>0.05)。结论瑞舒伐他汀在调脂治疗的同时降低GMP-140水平,有抑制血小板活化的作用。

作者关健谢晓明孙建丽

机构地区广东医学院附属医院心内科

出处《医药导报》 CAS 2015年第6期771-774,共4页 Herald of Medicine

关键词瑞舒伐他汀高血压高脂血症血小板

分类号 R972.6 [医药卫生—药品]

引文网络
相关文献

参考文献13

1阮长耿.血栓与止血[M].南京：江苏科技出版社,1994.64. 被引量：9
2赵文,吴高鹏.高血压病患者血小板参数的观察[J].上海医学检验杂志,2000,15(1):64-64. 被引量：10
3RIONDINO S, PIGNATELLI P, PULCINELLI FM, et al. Platelet hyperactivity in hypertensive older patients is controlled by lowering blood pressure [ J ]. J Am Geriatr Sic, 1999,47 ( 8 ) :943-947. 被引量：1
4杨天伦,夏珂.降压治疗对高血压患者血小板参数的影响[J].中华高血压杂志,2006,14(11):891-893. 被引量：11
5PUECETI'I L, BRUNI F, BOVA G, et al. Effect of diet and treatment with matins on platelet - dependent thrombin generation in hypercholesterolemic subjects [ J ]. Nutr Metab Cardiovasc Dis, 2001,11 ( 6 ) :378-387. 被引量：1
6MA L P, NIE D N, HSU S X, et al. Inhibition of platelet aggregation and expression of alpha granule membrane protein 140 and thromboxane B2 with pravastatin therapy for hypercholesterolemia[ J ]. J Assec Acad Minor Phys, 2002, 13(1) :23-26. 被引量：1
7SANTOS M, FUSET M, RUANO A, et al. Effect of atorv- astatin on platelet thromboxane A2 synthesis in aspirin- treated patients with acute myocardial infarction [ J ]. Am J Cardiol,2009,104 (12) : 1618- 1623. 被引量：1
8SCHAFER A, FRACCAROLLO D,VOGT C,et al. Improved endothelial function and reduced platelet activation by chronic HMG-CoA-reductase inhibition with rosuvastatin in rats with streptozotocin-induced diabetes mellitus [ J ]. Biochem Pharmacol,2007,73 (10) : 1367-1375. 被引量：1
9SHI J, WANG J, ZHANG H, et al. Statins increase throm- bomodulin expression and function in human endothelial cells by anitricoxide - dependent mechanism and counteract tumor necrosis factor [ J ]. Blood Coagul Fibrinolysis, 2003, 14(6) :575-585. 被引量：1
10骆高江,姜昌浩,陈智理,龚心琰.瑞舒伐他汀对慢性心力衰竭患者细胞因子及心功能的影响[J].医药导报,2013,32(1):44-47. 被引量：39

二级参考文献30

1汪明灯,高修仁.炎症细胞因子与慢性心力衰竭[J].新医学,2006,37(3):200-202. 被引量：34
2渠莉,王津文,于飞.他汀类药物的非调脂机制研究进展[J].中国医药,2006,1(6):379-381. 被引量：23
3[1]Okrucka a,Pechan J,Kratochvilova H.Effects of the angiotensin converting enzyme inhibitor perindopril on endothelial and platelet function in essential hypertension[J].Platelets,1998,9:63-67. 被引量：1
4[2]Keidar S,Oiknine J,Leiba A,et al.Fosinopril reduces ADP-induced platelet aggregation in hypertensive patients[J].Cardiovasc Pharmacol,1996,27:183-186. 被引量：1
5[5]Bath PM,Butterworth RJ.Platelet size:measurement,physiology and vascular disease[J].Blood Coagul Fibrinolysis,1996,7:157-61. 被引量：1
6[6]Riondino S,Pignatelli P,Pulcinelli FM,et al.Platelet hyperactivity in hypertensive older patients is controlled by lowering blood pressure[J].J Am Geriatr Sic,1999,47:943-947. 被引量：1
7[7]Sunil Nadar,Andrew DB,Gregory YH.Platelet morphology and plasma indices of platelet activation in essential hypertension:effect of amlodipine-based antihypertension therapy[J].Ann Med,2004,36:552-557. 被引量：1
8[8]Monton M,Jimenez A,Nunez A.Comparative effects of angiotensin Ⅱ AT1 type receptor antagonists in vitro on human platelet activation[J].J Cardiovasc Pharmacol,2000,35:903-906. 被引量：1
9[9]Li P,Ferrario CM,Brosnihan KB.Losartan inhibits thromboxane A2-induced platelet aggregation and vascular constriction in,spontaneously hypertensive rats[J].J Cardiovasc Pharmacol,1998,32:198-205. 被引量：1
10[10]Matys T,Kucharewicz I,Pawlak R,et al.Oxide-dependent antiplatelet action of AT1-receptor antagonists in a pulmonary thromboembolism in mice[J].J Cardiovasc Pharmacol,2003,42:710-713. 被引量：1